Affiance Financial LLC Purchases Shares of 1,800 Eli Lilly And Co (NYSE:LLY)

Affiance Financial LLC purchased a new stake in Eli Lilly And Co (NYSE:LLY) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,800 shares of the company’s stock, valued at approximately $201,000.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Eli Lilly And Co by 0.8% in the second quarter. Vanguard Group Inc. now owns 71,134,378 shares of the company’s stock valued at $7,880,977,000 after acquiring an additional 578,045 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Eli Lilly And Co by 1.5% in the second quarter. BlackRock Inc. now owns 61,979,145 shares of the company’s stock valued at $6,866,670,000 after acquiring an additional 898,845 shares in the last quarter. FMR LLC boosted its holdings in shares of Eli Lilly And Co by 1.7% in the first quarter. FMR LLC now owns 13,916,001 shares of the company’s stock valued at $1,805,741,000 after acquiring an additional 228,920 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Eli Lilly And Co by 0.3% in the second quarter. Northern Trust Corp now owns 11,056,098 shares of the company’s stock valued at $1,224,906,000 after acquiring an additional 32,421 shares in the last quarter. Finally, Nuveen Asset Management LLC boosted its holdings in shares of Eli Lilly And Co by 20,030.9% in the second quarter. Nuveen Asset Management LLC now owns 7,265,844 shares of the company’s stock valued at $804,983,000 after acquiring an additional 7,229,751 shares in the last quarter. Institutional investors own 76.72% of the company’s stock.

In related news, SVP Alfonso G. Zulueta sold 4,500 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $117.00, for a total value of $526,500.00. Following the completion of the transaction, the senior vice president now owns 33,806 shares of the company’s stock, valued at approximately $3,955,302. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Alfonso G. Zulueta sold 19,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $112.91, for a total transaction of $2,201,745.00. Following the completion of the transaction, the senior vice president now directly owns 38,306 shares of the company’s stock, valued at approximately $4,325,130.46. The disclosure for this sale can be found here. Insiders have sold 243,452 shares of company stock valued at $28,252,925 over the last 90 days. 0.11% of the stock is currently owned by insiders.

NYSE:LLY traded up $1.67 during trading hours on Friday, reaching $108.59. 26,519 shares of the company’s stock were exchanged, compared to its average volume of 3,133,175. The company has a market capitalization of $103.48 billion, a P/E ratio of 19.57, a price-to-earnings-growth ratio of 1.86 and a beta of 0.16. Eli Lilly And Co has a 12 month low of $104.17 and a 12 month high of $132.13. The company has a quick ratio of 0.87, a current ratio of 1.13 and a debt-to-equity ratio of 4.98. The business’s 50-day simple moving average is $111.56 and its two-hundred day simple moving average is $114.85.

Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Tuesday, July 30th. The company reported $1.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.45 by $0.05. The firm had revenue of $5.64 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Eli Lilly And Co had a net margin of 33.76% and a return on equity of 70.86%. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period last year, the firm posted $1.48 earnings per share. As a group, sell-side analysts anticipate that Eli Lilly And Co will post 5.73 earnings per share for the current fiscal year.

Several research analysts have recently issued reports on LLY shares. ValuEngine cut shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Friday, June 28th. Bank of America set a $120.00 price objective on shares of Eli Lilly And Co and gave the company a “neutral” rating in a report on Tuesday, September 10th. Nine investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $122.92.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: How to Invest in Stocks with Increasing Dividends

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.